Thymosin alpha-1 demonstrated safety and virological response in Japanese chronic hepatitis B patients in a randomized clinical trial, validating its efficacy in an Asian population.
Key findingThymosin alpha-1 showed safety and efficacy (HBeAg seroconversion, HBV DNA reduction) in Japanese chronic hepatitis B patients in a randomized control
What the researchers found
Thymosin alpha-1 showed safety and efficacy (HBeAg seroconversion, HBV DNA reduction) in Japanese chronic hepatitis B patients in a randomized controlled trial, validating immunotherapy-based HBV treatment in the high-prevalence Asian population.
Why it matters
Relevant for thymosin-alpha-1, infection, immune-function, clinical-trials.
How the study worked
RCT study on thymosin-alpha-1, infection.
What this study cannot tell us
See abstract.
How to read the evidence
strong evidence.
When this study was published
Published in 2005.
The bigger picture
Advances peptide research with clinical implications.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial.
Journal of viral hepatitis, 12(3), 300-6
Citation
Iino, S; Toyota, J; Kumada, H; Kiyosawa, K; Kakumu, S; Sata, M; Suzuki, H; Martins, E B. (2005). The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial.. Journal of viral hepatitis, 12(3), 300-6.